Northwest Biotherapeutics (OTCMKTS:NWBO) Releases Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $0.23 million during the quarter.

Northwest Biotherapeutics Trading Down 7.0 %

NWBO traded down $0.02 on Wednesday, reaching $0.21. The stock had a trading volume of 3,911,649 shares, compared to its average volume of 3,229,775. The business’s 50-day moving average price is $0.26 and its two-hundred day moving average price is $0.28. The company has a market cap of $293.89 million, a P/E ratio of -2.65 and a beta of -0.52. Northwest Biotherapeutics has a 12-month low of $0.20 and a 12-month high of $0.57.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.